AnuBio Joins ARIA's Sustained Viral Resilience Programme

Why do some people stay healthy when everyone around them is getting sick? That question is at the heart of a new project we're proud to be part of. AnuBio has been selected as part of one of 11 teams funded through the Advanced Research + Invention Agency (ARIA)'s £57m Sustained Viral Resilience programme. The project, "From Mechanism to Medicine," is led by Professor Ajit Lalvani at Imperial College London, alongside UCL and AnuBio. Together we're working to understand why some individuals resist respiratory viral infections despite exposure, and to turn those naturally protective immune mechanisms into a new class of medicines: sustained innate immunoprophylactics (SIIPs). AnuBio leads the project's machine learning and AI platform. We're integrating multiomic and clinical data and applying our TRAILBLAZER architecture to predict which SIIP candidates will actually protect patients. We're looking forward to building this with an exceptional team, and with the wider community of ARIA R&D Creators.